Title:
RECOMBINANT RHABDOVIRUSES AS LIVE-VIRAL VACCINES FOR IMMUNODEFICIENCY VIRUSES
Document Type and Number:
WIPO Patent Application WO2001055330
Kind Code:
A3
Abstract:
This invention provides recombinant, replication-competent Rhabdovirus vaccine strain-based expression vectors for expressing heterologous viral antigenic polypeptides such as immunodeficiency virus envelope proteins or subparts thereof. An additional transcription stop/start unit within the Rhabdovirus genome is inserted to express the heterologous antigenic polypeptides. The HIV-1 gp160 protein is stably and functionally expressed, as indicated by fusion of human T cell-lines after infection with the recombinant RVs. Inoculation of mice with the recombinant Rabies viruses expressing HIV-1 gp160 induces a strong humoral response directed against the HIV-1 envelope protein after a single boost with an isolated recombinant HIV-1 gp120 protein. Moreover, high neutralization titers, up to 1:800, against HIV-1 are detected in the mouse sera. These recombinant viral vectors expressing viral antigenic polypeptides provide useful and effective pharmaceutical compositions for the generation of viral-specific immune responses.
More Like This:
Inventors:
SCHNELL MATTHIAS J (US)
Application Number:
PCT/US2001/001989
Publication Date:
March 28, 2002
Filing Date:
January 22, 2001
Export Citation:
Assignee:
UNIV JEFFERSON (US)
SCHNELL MATTHIAS J (US)
SCHNELL MATTHIAS J (US)
International Classes:
C12N15/09; A61K35/76; A61K39/21; A61K48/00; A61P31/18; C07K14/16; C12N7/00; C12N15/86; A61K39/00; (IPC1-7): C12P21/06; A61K39/12; A61K39/205; A61K39/21; C12N7/04
Foreign References:
| US5789229A | 1998-08-04 | |||
| US6001634A | 1999-12-14 | |||
| US5780448A | 1998-07-14 |
Download PDF: